Navigation Links
If you think cancer genes are simple, you don't know JAK
Date:9/17/2007

Cancer-causing genes can work in more powerful and sneaky ways than have been realized. Scientists have shown that a gene named JAK that is closely related to a common cancer-causing gene in people tips the scales toward cancer in an unexpected manner. JAK disrupts the activity of an organisms DNA on a broad scale, thwarting a critical molecular event very early on in an embryos development.

A team from the University of Rochester Medical Center made the finding, published in the Sept. 7 issue of Public Library of Science (PLoS) Genetics, through research involving fruit flies, which share much of the same complex cellular signaling as humans. Sorting out the major molecular processes in fruit flies or other comparatively simple organisms first has often allowed scientists studying diseases like cancer to speed the development of new treatments by years or even decades.

By manipulating the DNA of fruit flies and analyzing their body types as they develop as maggots the team made a surprising finding: The cancer-promoting effects of a mutation to the DNA sequence of a gene that normally suppresses cancer can be passed from parents to offspring, even if the mutation itself is not passed to the offspring. Under some circumstances, having one parent with the mutation is enough to ultimately affect the offspring, even when the mutation itself is not passed to the next generation.

The work offers a stark illustration of a reality that scientists are coming to fully respect only recently: Even though the DNA code has been traditionally considered the only way to pass genetic information through the generations, there are other, more subtle genetic legacies, types of a molecular memory that can go from generation to generation as well.

The team made the finding with a cancer-causing gene, or oncogene, known as an activated JAK kinase. A biochemical system extremely similar to JAK is vital for peoples health, but when its signals
'/>"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. A High-Definition Hearing Aid that thinks for you
2. Stop and think before you eat
3. Healthcare Professionals Might Want To Rethink Their Dress Code
4. Positive Thinking
5. Thinking Could Be Affected Due To Hormone Therapy
6. Zinc increases thinking power of children
7. Inventive thinking in health promotion
8. Thin and don’t need exercise: think again!!
9. US Thinks About The Alternative Methods To Combat Bird Flu
10. Men Think Of Sex When They See A Woman For The First Time
11. Drug Regulators Need To Think In Long-Term, Say Charities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 27, 2014 Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ... injured by the medication are continuing to move forward ... looking ahead to a status conference in December, Bernstein ... Order issued earlier this year, a conference in the ... 10:00 a.m. Items likely to be discussed at the ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... 27, 2014 HealthPostures, a ... equipment , has announced that it has entered ... Environments. The partnership will put HealthPostures' products into ... , In addition to having its products sold ... promotes HealthPostures' products with the business decision makers ...
(Date:11/27/2014)... 2014 "The uglier, the better," says Dr. ... is full of laughter as we enjoy the ugly sweater ... a sweater from scratch. " It was a sight to ... that weren't ridiculous enough, the Christmas balls were faces of ... those interested in participating this year, it's simple to get ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, an ... will provide a 10% Christmas discount on PPC service. The ... The discount offer will begin on 1 December 2014 and ... About this offer, a PPC professional working at Ethane Web ... for small businesses, as this big discount would make the ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... to a hundred years ago are being used in the ... the first time old bones have been used in this ... combination of latest computer modelling techniques developed at the University ... of Bristol. With Engineering and Physical Sciences Research Council ...
... core professional obligation and lying, even for a patient, ... Jr., MD, FACP, president of the American College of ... internal medicine physician and medical student members today. ... "sick notes" issued without a medical evaluation to some ...
... HealthDay Reporter , MONDAY, Feb. 28 (HealthDay News) ... in which inflammation of the lining of the nose and ... the most severe cases, patients develop nasal polyps that can ... to begin with a steroid nasal spray and then move ...
... , MONDAY, Feb. 28 (HealthDay News) -- Few things send ... rising temperature. But, a new report from the American ... reminding parents that a fever is usually just the body,s ... actually prolong an illness. The AAP recommends that, in ...
... , MONDAY, Feb. 28 (HealthDay News) -- Heart ... positive outlook, researchers are reporting. More than 2,800 heart ... their belief in their ability to recover from the illness ... 1,637 of the patients had died. Of those deaths, 885 ...
... MONDAY, Feb. 28 (HealthDay News) -- The stress of ... and gain weight, researchers report. The Georgia Health ... 60 first-time mothers who were asked about their levels ... a low amount of physical activity, was most influenced ...
Cached Medicine News:Health News:Learning from old bones to treat modern back pain 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 3Health News:Kids' Fevers May Not Always Need Treatment 2Health News:Kids' Fevers May Not Always Need Treatment 3Health News:Stress May Help Spur Weight Gain in New Moms, Study Finds 2
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... GRONINGEN, Netherlands , July 26 ... organization providing testing services to support preclinical and clinical ... of Xendo Drug Development BV (XDD), headquartered in Groningen, ... organization (CRO), will be known as QPS Netherlands BV ...
... Harco Metal Products (Harco), an industry leader in tube ... contract to manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products ... risk and cost associated with staff injuries caused by physically lifting ...
Cached Medicine Technology:QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: